-

Media Alert for Durnell Supreme Court Argument

LEVERKUSEN, Germany & ST. LOUIS--(BUSINESS WIRE)--On April 27th, Monsanto will argue before the U.S. Supreme Court in Durnell v. Monsanto, a Roundup case involving the application of federal preemption under FIFRA. A favorable ruling by the Supreme Court would provide essential regulatory clarity for companies who seek to bring currently approved and new products to market, addressing their ability to serve U.S. farmers and consumers. Former Solicitor General Paul Clement will argue the case for Monsanto.

More than 100 government, farm, business and non-profit groups – including the U.S. government --joined amici briefs in support of Monsanto’s position, urging the nation’s highest court to affirm Congress’ intent in including a “Uniformity” provision in FIFRA, and prevent a patchwork of state laws and labelling requirements which would threaten businesses, the economy, and farmers. Read more about the amici support for Monsanto here.

Monsanto also released the following statement regarding the oral argument in Durnell:

“Congress enacted FIFRA to establish a uniform, nationwide framework governing pesticide registration and labeling, and companies should not face liability under state law for complying with federally approved and science-based labeling requirements. Allowing such claims to proceed invites a patchwork of state standards that conflict with the uniformity objective Congress prescribed in law and creates regulatory uncertainties that impede the development of new agricultural innovations. The security and affordability of the nation’s food supply depend on farmers’ and manufacturers’ ability to rely on the science-based judgments of federal regulators. Clarification from the Court is essential to restore uniformity, certainty, and the rule of law.”

Contacts

Media Contact:
Brian Leake
(314) 370.3285

Monsanto


Release Versions

Contacts

Media Contact:
Brian Leake
(314) 370.3285

More News From Monsanto

Court Grants Final Approval to Roundup™ Class Settlement

ST. LOUIS--(BUSINESS WIRE)--Today, a Missouri state court granted final approval of the U.S. nationwide class settlement designed to resolve current and future Roundup™ claims alleging non-Hodgkin's lymphoma (NHL) injuries through a long-term claims program. The Court’s final approval order is subject to appeal. The class settlement, combined with the U.S. Supreme Court’s favorable ruling in June in the Durnell case, are mutually reinforcing pillars in the company’s multipronged strategy design...

Bayer’s SUNHARBO® (asundexian) Now Available in the United States

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that SUNHARBO® (asundexian), 50 mg tablets, is now available to order in the United States. Hospitals, health systems and pharmacies have immediate access to order the product for inventory. SUNHARBO is the first approved Factor XIa inhibitor in the U.S. and represents the first in a new class of medicine.1 SUNHARBO is indicated in combination with antiplatelet therapy to reduce the risk of stroke in adults with recent non-cardioembolic isc...

Bayer’s SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Bayer’s SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, in Combination With Antiplatelet Therapy Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved SUNHARBO® (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa inhibitor indicat...
Back to Newsroom